Add BrightSurf on Google Email

Can AI help bridge the public health gap?

A new study by Ateneo researchers explores the cost-effectiveness of AI-assisted chest radiograph interpretation in isolated and disadvantaged Filipino communities. The study finds that AI-assisted interpretation is estimated to be more cost-effective than manual interpretation, with a potential annual cost savings of Php 877,330. The ...

SourceAteneo de Manila University·JournalBMC Health Services Research·DateSep 25, 2026

Preventive tuberculosis treatment wanes after one year in high-burden countries, but lasts for at least 8 to 13 years in low- and medium-burden countries

Researchers found strong initial protection from TB preventive treatment (TPT) in 24 countries, but long-term protection varied depending on TB disease burden. In high-burden settings, protection waned after just one year, while in low- and medium-burden settings, it lasted at least 8 and 13 years, respectively.

SourceBoston University School of Public Health·JournalThe Lancet Respiratory Medicine·TypeMeta-analysis·DateSep 22, 2026

New test could dramatically speed diagnosis of hard-to-detect lung infections

Researchers at Tulane University have developed a diagnostic platform that can identify the precise species of bacteria causing NTM lung disease infections within four hours. The platform, called CANDI, uses mucus from the lungs and other respiratory fluids to test for up to 15 clinically relevant species and subspecies of NTM bacteria.

SourceTulane University·JournalScience Translational Medicine·TypeExperimental study·DateSep 16, 2026

A pilot clinical trial led by Germans Trias provides the first clinical proof of concept for ibuprofen as an adjunctive treatment for tuberculosis

A pilot clinical trial assessed ibuprofen's safety and efficacy as an adjunct to standard TB treatment in patients with pre-XDR-TB and XDR-TB. Participants showed a reduced inflammatory response, indicating potential benefits for host-directed therapies.

SourceGermans Trias i Pujol Research Institute·JournalNature Communications·TypeRandomized controlled/clinical trial·DateJul 13, 2026

Tuberculosis vaccine changes brain’s immune environment and Alzheimer’s biomarkers in older adults

A new study found that BCG vaccines can modify Alzheimer's biomarkers in non-Alzheimer's participants, suggesting a potential biological explanation for the observed link between BCG vaccination and lower disease risk. The vaccine also promoted increased immune responses in healthy participants without Alzheimer's pathology.

SourceMass General Brigham·JournalCommunications Medicine·TypeRandomized controlled/clinical trial·DateJul 6, 2026

Expanded tuberculosis screening does not speed up treatment initiation or improve survival in hospitalized patients with HIV

A clinical trial found that adding molecular tests on urine and stool samples did not speed up treatment initiation or reduce mortality in hospitalized patients with HIV. The study showed no significant difference in treatment initiation within 72 hours between the expanded screening group and the standard group.

SourceBarcelona Institute for Global Health (ISGlobal)·JournalThe Lancet Infectious Diseases·TypeRandomized controlled/clinical trial·DateMay 8, 2026

Providing food baskets to people with tuberculosis is cost-effective and could avert over 100,000 deaths annually in India

Researchers found that providing food baskets to households affected by TB can prevent 10,470 years of poor health or early death for every 10,000 patients. The intervention is estimated to be cost-effective, costing $141 per health gain, and could avert approximately 120,000 TB deaths per year nationwide.

SourceBoston Medical Center·JournalBMJ Global Health·DateMay 4, 2026

Trial assesses safety and effectiveness of two new TB vaccines

Two new TB vaccines, VPM1002 and Immuvac, demonstrate safety and effectiveness in preventing progression to active TB in latent infection, particularly in children. However, they do not offer general protection against all forms of TB or prevent weight-related mortality.

SourceBMJ Group·JournalThe BMJ·TypeRandomized controlled/clinical trial·DateApr 9, 2026

Johns Hopkins team develops therapeutic, nasally delivered DNA vaccine for tuberculosis

The Johns Hopkins team developed a therapeutic intranasal DNA vaccine against tuberculosis that accelerated disease clearance, improved treatment outcomes, and stimulated immune responses. The vaccine combines two genes to direct the immune system to fight drug-tolerant bacterial persisters, showing promise for treating TB.

SourceJohns Hopkins Medicine·JournalJournal of Clinical Investigation·DateApr 1, 2026

Elucidating the functional dynamics of DNASE1L2 intron retention in tuberculosis progression

Researchers identify DNASE1L2 intron retention as a biomarker for TB progression and reveal its role in regulating inflammation. The study shows that upregulation of DNASE1L2-IR promotes host clearance of pathogen DNA, while downregulation weakens this antibacterial defense mechanism.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeExperimental study·DateMar 30, 2026

A study links armed conflict in Colombia with higher tuberculosis cases and mortality

A study by ISGlobal found that areas with high conflict intensity recorded a higher disease burden, including higher TB case rates and mortality. The research highlights the need for control strategies adapted to each territory, incorporating conflict-sensitive approaches into surveillance, prevention, and healthcare systems.

SourceBarcelona Institute for Global Health (ISGlobal)·JournalBMJ Global Health·TypeCase study·DateMar 30, 2026

Screening and preventive treatment program reduced tuberculosis incidence 83% among Tibetan children living in northern India

A recent study shows that a comprehensive TB screening and treatment program reduced TB incidence by 83% and prevalence of latent TB infection by 32% among Tibetan children in northern India. The program's success highlights the importance of community-led surveillance and treatment implementation to control TB transmission.

SourceJohns Hopkins Medicine·JournalThe Lancet Regional Health - Southeast Asia·DateMar 24, 2026

Foreign aid cuts to tuberculosis services could cost families $80 billion worldwide

A new study warns that reduced international funding for tuberculosis services could lead to significant economic hardship for 40 million households globally, with the poorest households bearing the greatest burden. The study estimates that complete elimination of external funding for TB could cost families up to $80 billion annually.

SourceBoston University School of Public Health·JournalPLOS Medicine·TypeComputational simulation/modeling·DateMar 11, 2026

Reduced international donor funding associated with higher household economic burden of Tuberculosis in low- and middle-income countries, according to modelling study

A modelling study suggests that reduced international donor funding increases the household economic burden of tuberculosis in low- and middle-income countries. The research found that decreased funding leads to a significant rise in healthcare costs and lost productivity.

SourcePLOS·JournalPLOS Medicine·TypeComputational simulation/modeling·DateFeb 27, 2026

Emerging class of antibiotics to tackle global tuberculosis crisis

A team of scientists at the University of Sydney has discovered how three naturally occurring antibiotic compounds disrupt the ClpC1–ClpP1P2 complex, a vital protein degradation machine in Mycobacterium tuberculosis. This finding uncovers surprising complexity and provides valuable insight into designing more effective anti-TB treatments.

SourceUniversity of Sydney·JournalNature Communications·TypeExperimental study·DateFeb 25, 2026

New clinical standards strengthen antimicrobial stewardship in tuberculosis care

The new clinical standards for antimicrobial stewardship in tuberculosis care aim to integrate TB into existing AMS frameworks, strengthening surveillance and resistance monitoring. The standards prioritize effectiveness, safety, and resistance prevention, promoting structured expert consultation services and targeted testing.

SourceGerman Center for Infection Research·JournalIJTLD OPEN·TypeSurvey·DateJan 6, 2026

Canada’s reduced pledge to Global Fund will impact domestic health

A reduced pledge by Canada to the Global Fund could lead to decreased success in controlling tuberculosis and HIV/AIDS in the country. The authors of an editorial urge Canada's government to invest in improving social determinants of health and implement disease-specific suggestions to address these pressing global health issues.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeCommentary/editorial·DateDec 15, 2025

Repurposed antibiotic shows promise against Central Nervous System Tuberculosis in NUS Medicine study

Researchers have demonstrated that doxycycline can improve survival rates and neurological outcomes in children with Central Nervous System Tuberculosis. The study found that treating CNS-TB laboratory models with doxycycline alongside standard TB drugs suppressed inflammation, preserved brain tissue, and improved vascular integrity.